1. Callaway E. Why does the Omicron sub-variant spread faster than the original? Nature. 2022;602(7898):556-7. DOI: 10.1038/d41586-022-00471-2
2. Jung C, Kmiec D, Koepke L, Zech F, Jacob T, Sparrer KMJ, et al. Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning? Journal of virology. 2022;96(6):e0207721. DOI: 10.1128/jvi.02077-21
3. Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185(3):467-84.e15. DOI: 10.1016/j.cell.2021.12.046
4. Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell. 2022. S0092-8674(22)00533-5. DOI: 10.1016/j.cell.2022.04.035
5. Planas D, Saunders N, Maes P, Guivel-Benhassine F, Planchais C, Buchrieser J, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602(7898):671-5. 10.1016/j.cell.2022.04.035
6. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447-56.e11. DOI: 10.1016/j.cell.2021.12.032
7. Cele S, Jackson L, Khoury DS, Khan K, Moyo-Gwete T, Tegally H, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602(7898):654-6. DOI: 10.1038/s41586-021-04387-1
8. Rössler A, Knabl L, von Laer D, Kimpel J. Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection. The New England journal of medicine. 2022. 386:1764-1766. DOI: 10.1056/NEJMc2201607
9. Medits I, Springer DN, Graninger M, Camp JV, Höltl E, Aberle SW, et al. Human primary Omicron BA.1 and BA.2 infections result in sub-lineage-specific neutralization (PREPRINT (Version 1) available at Research Square 2022 DOI: 10.21203/rs.3.rs-1536794/v1
10. Lippi G, Adeli K, Plebani M. Commercial immunoassays for detection of anti-SARS-CoV-2 spike and RBD antibodies: urgent call for validation against new and highly mutated variants. Clinical chemistry and laboratory medicine. 2021. DOI: 10.1515/cclm-2021-1287
11. GeurtsvanKessel CH, Okba NMA, Igloi Z, Bogers S, Embregts CWE, Laksono BM, et al. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. Nature communications. 2020;11(1):3436. DOI: 10.1038/s41467-020-17317-y
12. Olbrich L, Castelletti N, Schälte Y, Garí M, Pütz P, Bakuli A, et al. Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2. The Journal of general virology. 2021;102(10). DOI: 10.1099/jgv.0.001653
13. Semmler G, Traugott MT, Graninger M, Hoepler W, Seitz T, Kelani H, et al. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays. Journal of clinical microbiology. 2021;59(5). 10.1128/jcm.02890-20
14. Kristiansen PA, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet (London, England). 2021;397(10282):1347-8. 10.1016/s0140-6736(21)00527-4
15. Girl P, Zwirglmaier K, von Buttlar H, Wölfel R, Müller K. Evaluation of Two Rapid Lateral Flow Tests and Two Surrogate ELISAs for the Detection of SARS-CoV-2 Specific Neutralizing Antibodies. Frontiers in medicine. 2022;9:820151. DOI: 10.3389/fmed.2022.820151
16. Kohmer N, Rühl C, Ciesek S, Rabenau HF. Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies. Journal of clinical medicine. 2021;10(10): 2128. DOI: 10.3390/jcm10102128
17. Österreichische Gesellschaft für Ernährungssicherheit und Gesundheit GmBH - report of weekly detected variants of concern in 2022 in Austria. 2022 [Available from: https://www.ages.at/fileadmin/Corona/Varianten/Varianten_nach_KWs_2022-05-20.csv]
18. Koblischke M, Traugott MT, Medits I, Spitzer FS, Zoufaly A, Weseslindtner L, et al. Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity. Frontiers in medicine. 2020;7:592629. DOI: 10.3389/fmed.2020.592629
19. Sieber J, Mayer M, Schmidthaler K, Kopanja S, Camp JV, Popovitsch A, et al. Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron. Frontiers in immunology. 2022;13. DOI: 10.3389/fimmu.2022.882456
20. Graninger M, Camp JV, Aberle SW, Traugott M, Hoepler W, Puchhammer-Stöckl E, et al. Heterogeneous SARS-CoV-2-neutralizing activities after infection and vaccination. Frontiers in immunology. 2022. (accepted for publication). DOI: 10.3389/fimmu.2022.888794.
21. Arora P, Zhang L, Rocha C, Sidarovich A, Kempf A, Schulz S, et al. Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3. The Lancet Infectious diseases. 2022. S1473-3099(22)00224-9. DOI: 10.1016/s1473-3099(22)00224-9
22. Mykytyn AZ, Rissmann M, Kok A, Rosu ME, Schipper D, Breugem TI, et al. Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants. bioRxiv. 2022:2022.02.23.481644. DOI: 10.1101/2022.02.23.481644
23. Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al. Omicron sub-lineages BA.4/BA.5 escape BA.1 infection elicited neutralizing immunity. medRxiv. 2022:2022.04.29.22274477. DOI: 10.1101/2022.04.29.22274477
24. Radia T, Williams N, Agrawal P, Harman K, Weale J, Cook J, et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation. Paediatric respiratory reviews. 2021;38:51-7. DOI: 10.1016/j.prrv.2020.08.001
25. Rostad CA, Chahroudi A, Mantus G, Lapp SA, Teherani M, Macoy L, et al. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). Pediatrics. 2020;146(6). DOI: 10.1542/peds.2020-018242
26. Daniels CJ, Rajpal S, Greenshields JT, Rosenthal GL, Chung EH, Terrin M, et al. Prevalence of Clinical and Subclinical Myocarditis in Competitive Athletes With Recent SARS-CoV-2 Infection: Results From the Big Ten COVID-19 Cardiac Registry. JAMA cardiology. 2021;6(9):1078-87. DOI: 10.1001/jamacardio.2021.2065
27. Suh YJ, Hong H, Ohana M, Bompard F, Revel MP, Valle C, et al. Pulmonary Embolism and Deep Vein Thrombosis in COVID-19: A Systematic Review and Meta-Analysis. Radiology. 2021;298(2):E70-e80. DOI: 10.1148/radiol.2020203557
28. Brodin P, Arditi M. Severe acute hepatitis in children: investigate SARS-CoV-2 superantigens. The Lancet Gastroenterology & Hepatology. 2022. DOI: 10.1016/S2468-1253(22)00166-2
29. World Health Organization (23 April 2022). Disease Outbreak News; Multi-Country – Acute, severe hepatitis of unknown origin in children.
2022 [Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON376
30. Montesinos I, Dahma H, Wolff F, Dauby N, Delaunoy S, Wuyts M, et al. Neutralizing antibody responses following natural SARS-CoV-2 infection: Dynamics and correlation with commercial serologic tests. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2021;144:104988. DOI: 10.1016/j.jcv.2021.104988